List of Qulipta drug patents
Qulipta is owned by Abbvie Inc.
Qulipta contains Atogepant.
Qulipta has a total of 4 drug patents out of which 0 drug patents have expired.
Qulipta was authorised for market use on 28 September, 2021.
Qulipta is available in tablet;oral dosage forms.
Qulipta can be used as preventive treatment of episodic migraine in adults.
Drug patent challenges can be filed against Qulipta from 2025-09-28.
The generics of Qulipta are possible to be released after 30 January, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(8 years from now) | |
| US8754096 | ABBVIE INC | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(9 years from now) | |
| US9850246 | ABBVIE INC | Process for making CGRP receptor antagonists |
Mar, 2033
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117836 | ABBVIE INC | Tablet formulation for CGRP active compounds |
Jan, 2035
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 2025-09-28
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of episodic migraine in adults
Dosage: TABLET;ORAL
QULIPTA family patents
36
United States
9
European Union
4
China
4
Australia
3
Hong Kong
3
Canada
3
Japan
3
Korea, Republic of
3
Taiwan
2
Spain
2
Denmark
2
RS
2
Poland
2
Russia
2
Singapore
2
ME
2
Croatia
2
Cyprus
2
Israel
2
Portugal
2
Mexico
2
Slovenia
1
Dominican Republic
1
Malaysia
1
Brazil
1
Ukraine
1
Morocco
1
Argentina
1
EA
1
Nicaragua
1
New Zealand
1
Guatemala
1
Peru
1
Chile
1
Costa Rica
1
Ecuador
1
Colombia
1
Lithuania
1
Saudi Arabia
1
Tunisia
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic